文献速递姑息放疗与转移瘤胸部肿瘤放疗放疗物理与技术

寡转移性癌症患者接受转移灶导向立体定向体部放疗后的急性毒性:E2-RADIatE OligoCare队列的中期分析

Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort.
PubMed 文献 · Radiother Oncol · 2024-07-31

OligoCare是一项前瞻性、基于注册的单臂观察性研究,纳入接受立体定向体部放疗(SBRT)的实体瘤寡转移患者,本分析报告SBRT后6个月内急性毒性这一次要终点。

要点

  • 6例(0.4%)3级事件为脓胸、肺炎、放射性肺炎、放射性皮肤损伤、食欲下降和骨痛各1例。
  • 2例(0.1%)5级毒性为肺炎和脑出血。

核心结论

  • 作者认为OligoCare是规模最大的寡转移疾病前瞻性注册队列,6个月内急性毒性低,证实SBRT治疗寡转移的安全性。

研究设计与样本

  • OligoCare为前瞻性、基于注册、单臂、观察性研究,旨在报告接受SBRT的实体瘤寡转移患者的真实世界数据(NCT03818503)。
  • 本分析针对该研究的次要终点,即SBRT后6个月内的急性毒性;原发肿瘤包括非小细胞肺癌(NSCLC)、乳腺癌(BC)、结直肠癌(CRC)和前列腺癌(PC)。

主要发现

  • 按EORTC/ESTRO寡转移疾病(OMD)分类,新发OMD 828例(56%)、重复OMD 464例(32%)、诱导性OMD 176例(12%)。
  • SBRT相关急性≥3级不良事件报告于8例(0.5%)患者,其中致死性不良事件2例(0.1%)。
  • 6例(0.4%)3级事件为:脓胸1例、肺炎1例、放射性肺炎1例、放射性皮肤损伤1例、食欲下降1例、骨痛1例;其中NSCLC患者2例、BC患者2例、CRC与PC患者各1例。
  • 2例(0.1%)5级毒性为肺炎和脑出血。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate acute toxicity at 6 months after stereotactic body radiotherapy (SBRT) in patients with oligometastatic cancer within the OligoCare cohort. MATERIAL AND METHODS: OligoCare is a prospective, registry-based, single-arm, observational study that aims to report prospective real-world data of patients with oligometastases from solid cancer treated with SBRT (NCT03818503). Primary tumor included non-small cell lung cancer (NSCLC), breast cancer (BC), colorectal cancer (CRC), and prostate cancer (PC). This analysis addresses a secondary endpoint of the trial, acute toxicity within 6 months after SBRT. RESULTS: Out of 1,597registered patients, 1'468 patients were evaluated for acute toxicity. Globally, 290 (20 %) had NSCLC primary disease, 227 (16 %) had BC, 293 (20 %) had CRC, and 658 (45 %) had PC. Concomitant systemic treatment was administered in 527 (35.9 %) patients. According to the EORTC/ESTRO oligometastatic disease (OMD) classification, 828 (56 %) patients had de novo OMD, 464 (32 %) repeat OMD, and 176 (12 %) induced OMD. Acute grade ≥ 3 SBRT related adverse events were reported in 8 (0.5 %) patients, including 2 (0.1 %) fatal AEs. In particular, 6 (0.4 %) grade 3 events were: 1 empyema, 1 pneumonia, 1 radiation pneumonitis, 1 radiation skin injury, 1 decreased appetite, and 1 bone pain. Among those 2 occurred in NSCLC patients, 2 in BC patients, and 1 in CRC and PC patients each. The two (0.1 %) grade 5 toxicity were represented by: pneumonitis and cerebral hemorrhage. CONCLUSION: OligoCare is the largest prospective registry cohort on oligometastatic disease. Acute toxicity within 6 months was low, confirming the safety of SBRT in the treatment of oligometastases.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Alongi F, Nicosia L, Ricardi U, et al. Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohort. Radiother Oncol. 2024. PMID: 39094630. doi:10.1016/j.radonc.2024.110466

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。